Earlier today I looked at three ASX 200 shares that have been smashed in 2019.
Thankfully, these shares are in the minority, with the majority of shares on the index recording solid gains this year.
Three ASX 200 shares that are leading the way are listed below. Here’s why they have been on fire in 2019:
Avita Medical Ltd (ASX: AVH)
The Avita Medical share price has rocketed a remarkable 634% higher since the start of the year. The catalyst for this has been the strong sales growth of its RECELL System. The FDA-approved RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. It is used to prepare Spray-On Skin Cells using a small amount of a patient’s own skin. This provides a new way to treat severe burns, while significantly reducing the amount of donor skin required. Demand has been growing strongly, leading to Avita Medical recording first quarter sales of $7.9 million. This was a 165% increase on the prior corresponding period. This strong form recently allowed it to raise $120 million through an institutional placement. This will be used to fund its US growth and the pipeline development of new indications.
EML Payments Ltd (ASX: EML)
The EML Payments share price has been an impressive performer again this year, recording a gain of 188%. The catalyst for this has been its strong operating performance and a major acquisition. In FY 2019, EML Payments delivered a 37% increase in revenue and a 283% lift in net profit after tax. This strong form is expected to continue in FY 2020, with management guiding to EBITDA growth of 29% to 42%. This guidance excludes the $423 million acquisition of Ireland-based Prepaid Financial Services, which is expected to be significantly accretive to earnings in the future. The addition of Prepaid Financial Services has diversified its operations to include prepaid payments, digital banking capabilities, and other flexible software solutions to financial and non-financial institutions.
Polynovo Ltd (ASX: PNV)
The Polynovo share price has rocketed a massive 221% higher since the start of the year. This strong gain has been driven by excitement around its NovoSorb Biodegradable Temporising Matrix (BTM) product. The NovoSorb BTM product is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery or burns. Sales have been growing strongly and look set to be given a major boost in 2020. The medical device company recently revealed that NovoSorb BTM has been granted a certificate of conformance (CE Mark) approval for sale throughout UK/Ireland and the European Union. Management described this as a watershed moment for PolyNovo.
The post These ASX 200 shares have been on fire in 2019 appeared first on Motley Fool Australia.
If you missed these gains, I wouldn't worry. Because these high quality ASX shares have been tipped as market beaters in 2020.
Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares for 2019
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2019
- 5 Stocks for Potentially Building Wealth After 50
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Emerchants Limited. The Motley Fool Australia has recommended Emerchants Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019